Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial to evaluate the potential molecular profile of biliary tract cancer and also examine the clinical benefit and safety of panitumumab, cisplatin and gemcitabine in the treatment of biliary tract cancer

Next Previous
Trial Profile

Phase II trial to evaluate the potential molecular profile of biliary tract cancer and also examine the clinical benefit and safety of panitumumab, cisplatin and gemcitabine in the treatment of biliary tract cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panitumumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Biliary cancer; Gallbladder cancer
  • Focus Therapeutic Use
  • Acronyms TACTIC

    • Most Recent Events

    • 03 Jul 2012 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.
    • 17 Feb 2012 Planned initiation date changed from 1 Jun 2011 to 1 Jun 2012 as reported by Australian New Zealand Clinical Trials Registry.
    • 25 Mar 2011 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top